Kamada Ltd. (KMDA) To Go Ex-Dividend on August 27th

Kamada Ltd. (NASDAQ:KMDA) declared an annual dividend on Monday, August 17th. Investors of record on Thursday, August 27th will be given a dividend of 0.17 per share by the biotechnology company on Thursday, September 17th. This represents a dividend yield of 219.0%. The ex-dividend date is Thursday, August 27th.

Kamada has a payout ratio of 46.2% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Kamada to earn $0.60 per share next year, which means the company should continue to be able to cover its $0.18 annual dividend with an expected future payout ratio of 30.0%.

Kamada Stock Performance

Shares of Kamada stock opened at $7.89 on Wednesday. The company has a market cap of $453.71 million, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35. The firm has a 50-day simple moving average of $7.25 and a two-hundred day simple moving average of $7.94.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. The business had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%. Equities research analysts forecast that Kamada will post 0.49 EPS for the current year.

Institutional Investors Weigh In On Kamada

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aristides Capital LLC raised its stake in Kamada by 4.5% during the 1st quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 1,476 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Kamada by 9.2% in the fourth quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 4,870 shares in the last quarter. XTX Topco Ltd acquired a new stake in Kamada in the 4th quarter valued at about $103,000. Quadrature Capital Ltd increased its position in Kamada by 53.5% during the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 7,627 shares in the last quarter. Finally, Man Group plc increased its stake in Kamada by 19.9% in the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,684 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.